Parabilis Medicines, Inc.
Parabilis Medicines, Inc. (PBLS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ck0001657677-ex99_1.htm EX-99.1 EX-99.1 Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in
Biotech stocks hit 52-week highs Aug 4, 2026 after Q2 results or regulatory updates. UFP Technologies (UFPT) rose over 25% to $338.70, reporting Q2 net income $20.9M and sales $174M. InfuSystem (INFU) gained 33% to $12.49 on $36.9M Q2 revenue and 2026 guidance. Replimune (REPL) jumped to $13.86 after a favorable BLA opinion. SOPHiA (SOPH) rose to $6.98 with $23.3M Q2 revenue and 2026 outlook. Parabilis (PBLS) reached $36.69.
RA CAPITAL MANAGEMENT, L.P. purchased 244,593 indirectly-held shares of Parabilis Medicines, Inc. (PBLS) at an average of $28.29 ($27.13–$30.00, $6.92M total) across 6 trades over 2026-07-20 to 2026-07-22.
Over the past 7 days, alphai's AI scored 1 news story mentioning PBLS (Parabilis Medicines, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PBLS coverage spans insider activity, earnings and market movers.
In the last 30 days, PBLS insiders filed 6 SEC Form 4 transactions — 6 purchases ($6.9M) and no sales. The most active reporter was RA CAPITAL MANAGEMENT, L.P. with 6 filings.
Near-term catalyst is the disclosed cash runway and specific 2026 to 2027 clinical and FDA engagement milestones, plus non-dilutive funding from the Regeneron deal.
Clinical-stage FDA designations and early trial progress are the key narrative catalysts behind the move.
The filing signals continued accumulation by a large shareholder, but it is not a fundamental catalyst like guidance, trial results, or a deal.
Initiation can spark speculative interest, particularly in smaller biotech.
Large insider-style accumulation via a 10% owner purchase can modestly support sentiment, but it is not a new operating catalyst.
alphai scores every news story that mentions PBLS with an AI model for sentiment and relevance, and aggregates insider trades from Parabilis Medicines, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Parabilis Medicines, Inc. (PBLS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ck0001657677-ex99_1.htm EX-99.1 EX-99.1 Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in
5 min readBiotech stocks hit 52-week highs Aug 4, 2026 after Q2 results or regulatory updates. UFP Technologies (UFPT) rose over 25% to $338.70, reporting Q2 net income $20.9M and sales $174M. InfuSystem (INFU) gained 33% to $12.49 on $36.9M Q2 revenue and 2026 guidance. Replimune (REPL) jumped to $13.86 after a favorable BLA opinion. SOPHiA (SOPH) rose to $6.98 with $23.3M Q2 revenue and 2026 outlook. Parabilis (PBLS) reached $36.69.
6 min readRA CAPITAL MANAGEMENT, L.P. purchased 244,593 indirectly-held shares of Parabilis Medicines, Inc. (PBLS) at an average of $28.29 ($27.13–$30.00, $6.92M total) across 6 trades over 2026-07-20 to 2026-07-22.
2 min readOn July 6, 2026, analyst actions included T-Mobile US (TMUS) upgraded to Buy by Bank of America with a $220 target, and Gilead Sciences (GILD) upgraded to Buy by HSBC with a $155 target. Datadog (DDOG) was downgraded to Market Perform by Bernstein; HSBC cut Pfizer (PFE) to Hold. The article also cites mixed rates, gold up ~2%, and Bitcoin above $61,000.
5 min readLevy Guy purchased 500,000 indirectly-held shares of Parabilis Medicines, Inc. (PBLS) at $20.00 ($10.00M total) across 2 trades on 2026-06-11.
2 min readParabilis Medicines (NASDAQ: PBLS) raised in a June 10 IPO at $20 and closed up 58% on its first day. In its pipeline, zolucatetide is set for Phase 3 in 2027 and is designed to block a Wnt pathway protein-protein interaction. In a Phase 1/2 desmoid tumor study, updated data showed tumor reductions in all 25 evaluable patients, 74% ORR (19 patients), and no high-grade toxicity. Regeneron signed a May 2026 deal providing $50 million cash, $75 million equity, and up to $2.2 billion in milestones.
6 min readSEBULSKY ALAN purchased 17,500 indirectly-held shares of Parabilis Medicines, Inc. (PBLS) at an average of $27.06 ($26.00–$27.67, $0.47M total) across 3 trades over 2026-06-12 to 2026-06-15.
2 min readRA CAPITAL MANAGEMENT, L.P. purchased 21,188,750 indirectly-held shares of Parabilis Medicines, Inc. (PBLS) at $20.00 ($423.78M total) across 2 trades on 2026-06-11.
2 min readSEBULSKY ALAN purchased 12,500 indirectly-held shares of Parabilis Medicines, Inc. (PBLS) at $20.00 ($0.25M total) on 2026-06-11.
1 min readParabilis Medicines (NASDAQ: PBLS) raised $670 million in its IPO, the article says, after the stock jumped 58% on its first day to close at just over $31. The company plans to fund zolucatetide’s Phase 3 desmoid tumor study and earlier trials with proceeds. Parabilis reported a $145 million loss in the prior year, with $125 million in R&D, according to its prospectus.
6 min read